Alpha Tau Medical (DRTS) Net Cash Flow (2021 - 2022)

Alpha Tau Medical (DRTS) posted Net Cash Flow of -$86.3 million for Q2 2022, down 214.92% sequentially from $75.1 million in Q1 2022.

Alpha Tau Medical (DRTS) Net Cash Flow (2021 - 2022) Analysis & Trends

Alpha Tau Medical has reported Net Cash Flow for 2 years, with the latest figure at -$86.3 million in Q2 2022.

Quarterly Net Cash Flow changed N/A year-over-year to -$86.3 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was -$86.3 million (down 214.92% YoY) and the FY2025 annual result came in at -$1.5 million, down 248.61% from the prior year.
Net Cash Flow fell to -$86.3 million in Q2 2022 per DRTS's latest filing, from $75.1 million in the prior quarter.
Over five years, Net Cash Flow peaked at $75.1 million in Q1 2022 and troughed at -$86.3 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	652.90 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-504.30 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	374.50 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	407.41 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	17.81 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	225.59 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-496,000.00
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-37.14 Mn
10	Alpha Tau Medical	1.32 Bn	1.32 Bn	-	-

Download Data